{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069155","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.711649+00:00","generated_at":"2026-05-21T23:06:08.834620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met","bullets":["Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.","Cash and marketables $193.4M at March 31; plus $33.8M tax refund in April; expects runway into fiscal 2028.","Phase 2 RSVHR study of zelicapavir met enrollment target of 180 high-risk adults; topline data expected late Q3 2025.","STAT6 program: plan to select development candidate in 2H 2025; KIT inhibitor EPS-1421 IND-enabling studies ongoing.","Filed opening brief in patent infringement appeal against Pfizer over Paxlovid; original case filed June 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069155","json":"https://secwatch.observer/filing/0000950170-25-069155.json","markdown":"https://secwatch.observer/filing/0000950170-25-069155.md","text":"https://secwatch.observer/filing/0000950170-25-069155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/0000950170-25-069155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:06:08.834620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}